Physician profile
Niraj Khandelwal
NPI 1619186228
$4,378.98
in general payments reported to CMS, 2019-2025
33 companies · $864 in 2025
The $864 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $756 · 2020: $253 · 2021: $218 · 2022: $574 · 2023: $707 · 2024: $1,007 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,578.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,061.18 | 2019-2025 | |
| Janssen Biotech, INC. | $376.06 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $346.73 | 2019-2025 | Entyvio, Gattex |
| Gilead Sciences, INC. | $343.93 | 2022-2025 | Livdelzi, Epclusa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $340.28 | 2019-2025 | Xifaxan, Trulance |
| Braintree Laboratories, INC. | $239.12 | 2019-2023 | Suflave |
| Qol Medical, LLC | $208.14 | 2023-2025 | Sucraid, Sucraid |
| Pfizer INC. | $168.28 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $145.94 | 2020-2023 | Linzess |
| Genzyme Corporation | $111.64 | 2024 | |
| Lilly USA, LLC | $107.91 | 2024-2025 | Omvoh |
| Celgene Corporation | $96.33 | 2022-2024 | Zeposia |
| Madrigal Pharmaceuticals | $82.86 | 2024-2025 | Rezdiffra, Resmetirom |
| Boston Scientific Corporation | $82.20 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $75.77 | 2021-2025 | Ocaliva |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $73.81 | 2019-2025 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $68.76 | 2023-2024 | Dupixent |
| Phathom Pharmaceuticals, INC. | $54.24 | 2025 | Voquezna |
| Amgen INC. | $51.69 | 2021-2022 | |
| Romark Laboratories, Lc | $45.72 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $43.60 | 2024-2025 | Iqirvo |
| Organon LLC | $43.36 | 2024-2025 | Hadlima, Renflexis |
| Merck Sharp & Dohme LLC | $39.34 | 2019-2024 | Dificid |
| Allergan, INC. | $37.54 | 2019 | |
| Orphalan INC | $20.75 | 2025 | Cuvrior |
| Fresenius Kabi USA, LLC | $17.16 | 2024 | Idacio |
| Nestle Healthcare Nutrition INC. | $15.90 | 2022 | |
| Esperion Therapeutics, INC. | $14.86 | 2020 | |
| Aimmune Therapeutics, INC. | $14.51 | 2025 | Vowst |
| Redhill Biopharma INC. | $14.16 | 2021 | |
| Mauna Kea Technologies, INC. | $14.02 | 2025 | |
| Daiichi Sankyo INC. | $11.77 | 2020 | |
| Alexion Pharmaceuticals, INC. | $11.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niraj Khandelwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.